The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study
There has been an explosion of research on the potential benefits of the social neuropeptide oxytocin for a number of mental disorders including substance use disorders. Recent evidence suggests that intranasal oxytocin has both direct anti-addiction effects and pro-social effects that may facilitate engagement in psychosocial treatment for substance use disorders.
We aimed to assess the tolerability of intranasal oxytocin and its effects on heroin craving, implicit association with heroin and social perceptual ability in opioid-dependent patients receiving opioid replacement therapy (ORT) and healthy control participants.
We performed a randomized, double-blind, placebo-controlled, within- and between-subjects, crossover, proof-of-concept trial to examine the effects of oxytocin (40 international units) on a cue-induced craving task (ORT patients only), an Implicit Association Task (IAT), and two social perception tasks: the Reading the Mind in the Eyes Task (RMET) and The Awareness of Social Inference Test (TASIT).
Oxytocin was well tolerated by patients receiving ORT but had no significant effects on craving or IAT scores. There was a significant reduction in RMET performance after oxytocin administration versus placebo in the patient group only, and a significant reduction in TASIT performance after oxytocin in both the patient and healthy control groups.
A single dose of intranasal oxytocin is well tolerated by patients receiving ORT, paving the way for future investigations. Despite no significant improvement in craving or IAT scores after a single dose of oxytocin and some evidence that social perception was worsened, further investigation is required to determine the role oxytocin may play in the treatment of opioid use disorder.
Clinical Trial Registration
Methadone Oxytocin Option. ClinicalTrials.gov identifier: NCT01728909
KeywordsOxytocin Heroin Opioid Addiction Tolerability Craving Implicit Social RMET Clinical
- Bartz JA, Zaki J, Bolger N, Ochsner KN (2011) Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci 15(7):301–319Google Scholar
- Black Tar Heroin: The Dark End of the Street (1999) Directed by OKAZAKI, S. United States: Farallon FilmsGoogle Scholar
- Carson DS, Guastella AJ, Taylor ER, Mcgregor IS (2013) A brief history of oxytocin and its role in modulating psychostimulant effects. J Psychopharmacol 27(3):231–247Google Scholar
- Kornreich C, Foisy M-L, Philippot P, Dan B, Tecco J, Noël X, Hess U, Pelc I, Verbanck P (2003) Impaired emotional facial expression recognition in alcoholics, opiate dependence subjects, methadone maintained subjects and mixed alcohol-opiate antecedents subjects compared with normal controls. Psychiatry Res 119:251–260CrossRefPubMedGoogle Scholar
- Lane KA, Banaji MR, Nosek BA, Greenwald AG (2007) Understanding and using the implicit association test: IV. In: Wittenbrink B, Schwarz N (eds) Implicit measures of attitudes. New York, The Guilford Press, pp 59–102Google Scholar
- Lee MR, Glassman M, King-Casas B, Kelly DL, Stein EA, Schroeder J, Salmeron BJ (2014) Complexity of oxytocin׳ s effects in a chronic cocaine dependent population. Eur Neuropsychopharmacol 24:1483–1491Google Scholar
- Lindgren KP, Neighbors C, Westgate E, Salemink E (2014) Self-control and implicit drinking identity as predictors of alcohol consumption, problems, and cravings. J Stud Alcohol Drugs 75:290Google Scholar
- Mcgregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long‐term adverse consequences of drug use? Br J Pharmacol 154:358–368Google Scholar
- NIDA 2012. Mental Health Services Administration (2012) Results from the 2011 national survey on drug use and health: summary of national findings. NSDUH Series H-44, HHS Publication No (SMA), 12–4713Google Scholar
- Norman GJ, Cacioppo JT, Morris JS, Karelina K, Malarkey WB, Devries AC, Berntson GG (2011) Selective influences of oxytocin on the evaluative processing of social stimuli. J Psychopharmacol 25(10):1313–1319Google Scholar
- Pedersen CA, Boccia ML, Kampov-Polevoi A (2011) Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders. Google PatentsGoogle Scholar